Owlstone Medical said today that it inked a strategic collaborative deal with Johnson & Johnson‘s (NYSE:JNJ) Actelion to discover and validate a breath-based test intended for the early diagnosis of pulmonary hypertension and its subtypes. Cambridge, UK-based Owlstone Medical said that the collaborative development program will be funded solely by Actelion, and that it will initially […]
Owlstone Medical raises $50m
Owlstone Medical said today it raised $50 million (UK £38 million) in a new round of financing, with funds slated to help support the targeted launch of its breath biopsy kits and continued development of its technology platforms. The funding includes an initial $15 million (UK £11 million) the U.K.-based company reported raising in March, and […]
AstraZeneca taps Owlstone’s breath biopsy device to identify asthma, COPD biomarkers
Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today. Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can […]
Owlstone Medical raises $15m to commercialize breath biopsy platform
Owlstone Medical touted today that it raised $15 million to support the commercialization of its breathalyzer diagnostic device. Funds from the round, co-led by Horizons Ventures and Aviva Ventures, will also be used to expand the company’s pipeline and the precision medicine services that it provides to the pharma industry, according to the Cambridge, England-based […]
GSK to use Owlstone’s breath biopsy device in Phase II COPD trial
GlaxoSmithKline (NYSE:GSK) is slated to use Owlstone Medical‘s breath biopsy device in a phase II trial of its drug for chronic obstructive pulmonary disease, danirixin. The diagnostics company’s breathalyzer will be used to help GSK identify which patients will most benefit from the drug, as well as evaluate the effects of danirixin, according to the pharma company. Get […]
7 medtech stories we missed this week: July 14, 2017
From Novarad touting its VR-surgical guidance system to Zynex paying off its $2.2M loan, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Stimwave announces first patient in Brazil Stimwave announced in a July 5 press release that its first patients in Brazil have received Stimwave’s wireless pain relief […]
7 medtech stories we missed this week: April 21, 2017
From new and renewed partnerships to FDA approvals, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Life Spine receives FDA clearance for cervical spacer system Life Spine announced in an April 19 press release that it has received FDA 510(k) clearance for its Plateau-C Ti Cervical Spacer […]
7 disruptive innovations from medical device suppliers
Sometimes an innovation out of a contract manufacturer is truly disruptive when it comes to its potential for the medical device industry. Chris Newmarker, Managing Editor People sometimes make the mistake of viewing innovation as the product of a few geniuses and mavericks. But in fact, it is often the result of teamwork, as the […]
Pump makes breath biopsy more than a pipe dream
A micropump from TTP Ventus is enabling such innovations as Owlstone Medical‘ s breath biopsy technology, which is designed to detect early lung or bowel cancers through volatile organic compounds (VOCs). Officials at The Technology Partnership specifically spun out TTP Ventus to help commercialize the second generation of its signature product Disc Pump. Get the […]
Owlstone Medical launches 1,400-patient study for colon cancer ‘breathalyzer’
Owlstone Medical said today it is launching a 1,400-patient clinical trial of its breath-based colorectal cancer diagnostic technology. The Intercept trial aims to explore the accuracy of the U.K.-based company’s ‘breathalyzer’ test in detecting colorectal cancer at an early stage. Owlstone’s breathalyzer uses field asymmetric ion mobility spectrometry to detect volatile organic compound metabolites in […]
Owlstone Medical raises $11.6m for disease breathalyzer device
Owlstone Medical said today that it raised $11.6 million to help fund its disease breathalyzer device. The round was led by existing investors and follows an original investment of $7 million that spun the Cambridge, England-based company out in June last year. The funds will be used to commercially launch Owlstone’s breath biomaker R&D services, […]
MassDevice Network
@MassDevice
LinkedIn
YouTube